Ulviprubart
Term · Oncology and biomedicine · MLC-T-ONC-017395
A humanized, afucosylated monoclonal antibody directed against killer cell lectin-like receptor G1 (KLRG1), with potential immunomodulatory activity. Upon administration, anti-KLRG1 monoclonal antibody ABC008 targets and binds to KLRG1 expressed on highly differentiated effector CD8+ cytotoxic T cells, and selectively depletes these highly differentiated cytotoxic T cells while sparing other immune cells. This prevents the killing of cells by these highly differentiated cytotoxic T cells in certain autoimmune diseases, such as the destruction of muscle tissue in inclusion body myositis, and the destruction of neutrophils and red blood cell precursors in T-cell large granular lymphocytic leukemia (T-LGLL).
| Identifier | MLC-T-ONC-017395 |
|---|---|
| Field | Oncology and biomedicine |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-017395",
"term": "Ulviprubart",
"field": "Oncology and biomedicine",
"definition": "A humanized, afucosylated monoclonal antibody directed against killer cell lectin-like receptor G1 (KLRG1), with potential immunomodulatory activity. Upon administration, anti-KLRG1 monoclonal antibody ABC008 targets and binds to KLRG1 expressed on highly differentiated effector CD8+ cytotoxic T cells, and selectively depletes these highly differentiated cytotoxic T cells while sparing other immune cells. This prevents the killing of cells by these highly differentiated cytotoxic T cells in certain autoimmune diseases, such as the destruction of muscle tissue in inclusion body myositis, and the destruction of neutrophils and red blood cell precursors in T-cell large granular lymphocytic leukemia (T-LGLL).",
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/ulviprubart/"
}
Record 16,916 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.